A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
296actual
Sites
166
Countries
Argentina, Australia, Belgium +20
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2017-04-27 | actual | When the study began enrolling |
| Primary completion | 2020-03-20 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2017-02-14 | actual | When this record first appeared on the registry |
| Results posted | 2021-04-01 | actual | When the sponsor posted results to the registry |
| Record updated | 2025-11-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Carcinoma, Non-Small-Cell Lung
Interventions
- Drug: Lorlatinib — also filed as PF-06463922
- Drug: Crizotinib — also filed as Xalkori
Primary outcome
what the primary-completion date above is the date OFProgression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) Assessment
measured From time of Study Start up to 33 months
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2019-10-04 · 4.1 MB · Prot_001.pdf
Statistical Analysis Planposted 2020-05-26 · 18.5 MB · SAP_000.pdf
Publications
- PMID 41124598 — linked by the registry
- PMID 40024442 — linked by the registry
- PMID 39360949 — linked by the registry
- PMID 38819031 — linked by the registry
- PMID 37295609 — linked by the registry
- PMID 36535300 — linked by the registry
- PMID 35605188 — linked by the registry
- PMID 34585621 — linked by the registry
- PMID 33207094 — linked by the registry
- PMID 29074098 — linked by the registry
- PMID 28501139 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed